Detalhes do Documento

Outcomes of cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after the acute phase

Autor(es): van de Munckhof, Anita ; Lindgren, Erik ; Kleinig, Timothy J. ; Field, Thalia S. ; Cordonnier, Charlotte ; Krzywicka, Katarzyna ; Poli, Sven ; Sánchez van Kammen, Mayte ; Borhani-Haghighi, Afshin ; Lemmens, Robin ; Scutelnic, Adrian ; Ciccone, Alfonso ; Gattringer, Thomas ; Wittstock, Matthias ; Dizonno, Vanessa ; Devroye, Annemie ; Elkady, Ahmed ; Günther, Albrecht ; Cervera, Alvaro ; Mengel, Annerose ; Chew, Beng Lim Alvin ; Buck, Brian ; Zanferrari, Carla ; Garcia-Esperon, Carlos ; Jacobi, Christian ; Soriano, Cristina ; Michalski, Dominik ; Zamani, Zohreh ; Blacquiere, Dylan ; Johansson, Elias ; Cuadrado-Godia, Elisa ; Vuillier, Fabrice ; Bode, Felix J. ; Caparros, François ; Maier, Frank ; Tsivgoulis, Georgios ; Katzberg, Hans D. ; Duan, Jiangang ; Burrow, Jim ; Pelz, Johann ; Mbroh, Joshua ; Oen, Joyce ; Schouten, Judith ; Zimmermann, Julian ; Ng, Karl ; Garambois, Katia ; Petruzzellis, Marco ; Carvalho Dias, Mariana ; Ghiasian, Masoud ; Romoli, Michele ; Miranda, Miguel ; Wronski, Miriam ; Skjelland, Mona ; Almasi-Dooghaee, Mostafa ; Cuisenier, Pauline ; Murphy, Seán ; Timsit, Serge ; Coutts, Shelagh B. ; Schönenberger, Silvia ; Nagel, Simon ; Hiltunen, Sini ; Chatterton, Sophie ; Cox, Thomas ; Bartsch, Thorsten ; Shaygannejad, Vahid ; Mirzaasgari, Zahra ; Middeldorp, Saskia ; Levi, Marcel M. ; Kremer Hovinga, Johanna A. ; Jood, Katarina ; Tatlisumak, Turgut ; Putaala, Jukka ; Heldner, Mirjam R. ; Arnold, Marcel ; de Sousa, Diana Aguiar ; Ferro, José ; Coutinho, Jonathan M.

Data: 2022

Identificador Persistente: http://hdl.handle.net/10451/54475

Origem: Repositório da Universidade de Lisboa

Assunto(s): Hospitalization; Intracranial thrombosis; Mortality; Thrombocytopenia; Vaccination; Venous thrombosis


Descrição

Background: Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe condition, with high in-hospital mortality rates. Here, we report clinical outcomes of patients with CVT-VITT after SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination who survived initial hospitalization. Methods: We used data from an international registry of patients who developed CVT within 28 days of SARS-CoV-2 vaccination, collected until February 10, 2022. VITT diagnosis was classified based on the Pavord criteria. Outcomes were mortality, functional independence (modified Rankin Scale score 0–2), VITT relapse, new thrombosis, and bleeding events (all after discharge from initial hospitalization). Results: Of 107 CVT-VITT cases, 43 (40%) died during initial hospitalization. Of the remaining 64 patients, follow-up data were available for 60 (94%) patients (37 definite VITT, 9 probable VITT, and 14 possible VITT). Median age was 40 years and 45/60 (75%) patients were women. Median follow-up time was 150 days (interquartile range, 94–194). Two patients died during follow-up (3% [95% CI, 1%–11%). Functional independence was achieved by 53/60 (88% [95% CI, 78%–94%]) patients. No new venous or arterial thrombotic events were reported. One patient developed a major bleeding during follow-up (fatal intracerebral bleed). Conclusions: In contrast to the high mortality of CVT-VITT in the acute phase, mortality among patients who survived the initial hospitalization was low, new thrombotic events did not occur, and bleeding events were rare. Approximately 9 out of 10 CVT-VITT patients who survived the acute phase were functionally independent at follow-up.

Tipo de Documento Artigo científico
Idioma Inglês
Contribuidor(es) Repositório Científico de Acesso Aberto da ULisboa
facebook logo  linkedin logo  twitter logo 
mendeley logo

Documentos Relacionados

Não existem documentos relacionados.